Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT00517790. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study identification
- NCT ID
- NCT00517790
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Enrollment
- 140 participants
Conditions and interventions
Conditions
Interventions
- ABT-869 .25 mg/kg Drug
- ABT-869 0.10 mg/kg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2007
- Primary completion
- May 31, 2011
- Completion
- May 31, 2012
- Last update posted
- Apr 4, 2013
2007 – 2012
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 7194 | Fountain Valley | California | 92708 | — |
| Site Reference ID/Investigator# 5617 | Los Angeles | California | 90033 | — |
| Site Reference ID/Investigator# 7934 | Sacramento | California | 95817 | — |
| Site Reference ID/Investigator# 5646 | Aurora | Colorado | 80045-0510 | — |
| Site Reference ID/Investigator# 6627 | Waterbury | Connecticut | 06708 | — |
| Site Reference ID/Investigator# 7868 | Newark | Delaware | 19718 | — |
| Site Reference ID/Investigator# 7616 | Port Saint Lucie | Florida | 34952 | — |
| Site Reference ID/Investigator# 5648 | Chicago | Illinois | 60637 | — |
| Site Reference ID/Investigator# 6739 | Evanston | Illinois | 60201 | — |
| Site Reference ID/Investigator# 8100 | Harvey | Illinois | 60426 | — |
| Site Reference ID/Investigator# 5269 | Indianapolis | Indiana | 46202 | — |
| Site Reference ID/Investigator# 6042 | St Louis | Missouri | 63110 | — |
| Site Reference ID/Investigator# 6680 | East Orange | New Jersey | 07018 | — |
| Site Reference ID/Investigator# 5603 | Voorhees Township | New Jersey | 08043 | — |
| Site Reference ID/Investigator# 5652 | Buffalo | New York | 14263 | — |
| Site Reference ID/Investigator# 6184 | Charlotte | North Carolina | 28211 | — |
| Site Reference ID/Investigator# 6777 | Greensboro | North Carolina | 27403 | — |
| Site Reference ID/Investigator# 5650 | Memphis | Tennessee | 38120 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00517790, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2013 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00517790 live on ClinicalTrials.gov.